idarubicinol has been researched along with Hodgkin Disease in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cocorocchio, E; Corsini, C; D'Incalci, M; Ferrucci, PF; Ghielmini, M; Mancuso, P; Martinelli, G; Mezzetti, M; Mori, A; Paolucci, M; Riggi, M; Tealdo, F; Zucchetti, M | 1 |
1 other study(ies) available for idarubicinol and Hodgkin Disease
| Article | Year |
|---|---|
Idarubicinol myelotoxicity: a comparison of in vitro data with clinical outcome in patients treated with high-dose idarubicin.
Topics: Adult; Antineoplastic Agents; Daunorubicin; Hematopoietic Stem Cells; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Treatment Outcome | 2000 |